Acme Idea Company

Acelyrin is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for patients with serious diseases, with a primary emphasis on immunology and inflammation. The company's lead program is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency and small size, allowing for high-exposure subcutaneous dosing. Acelyrin is currently advancing izokibep through late-stage clinical trials for indications including hidradenitis suppurativa and psoriatic arthritis. In addition to its lead asset, the company is developing lonigutamab for thyroid eye disease and SLRN-517 for chronic urticaria. Founded by industry veterans, the company aims to identify and accelerate the development of high-value assets that can provide meaningful clinical benefits over existing standards of care.